A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer (Q46699227)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer |
scientific article |
Statements
1 reference
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer (English)
1 reference
A L Cohn
1 reference
J Maurel
1 reference
E Nowara
1 reference
J Sastre
1 reference
B Y S Chuah
1 reference
M V Kopp
1 reference
D D Sakaeva
1 reference
E P Mitchell
1 reference
S Dubey
1 reference
S Suzuki
1 reference
Y-J Hei
1 reference
F Galimi
1 reference
I McCaffery
1 reference
Y Pan
1 reference
R Loberg
1 reference
S Cottrell
1 reference
S-P Choo
1 reference
19 March 2013
1 reference
1 reference
24
1 reference
7
1 reference
1777-1785
1 reference
Identifiers
1 reference
1 reference